Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kuvan in Schizophrenia and Schizoaffective Disorder
NCT01706965Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2012
- Primary completion
- Jun 2016
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of sapropterin in schizophrenia, schizoaffective disorder, sponsored by New York State Psychiatric Institute. Started Oct 2012; status: completed.
02
Drugs
sapropterin
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT01706965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01706965.